Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSE3WP)

Drug Name
PF-06260414 Drug Info
Synonyms PF-14
Indication
Disease Entry ICD 11 Status REF
Cachexia MG20 Discontinued in Phase 1 [1]
Pain MG30-MG3Z Investigative [2]
Cross-matching ID
PubChem CID
76071881
CAS Number
CAS 1612755-71-1
TTD Drug ID
DMSE3WP

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Androgen receptor (AR) DTT AR 5.955 4.868 5.902 5.567
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cachexia
ICD Disease Classification MG20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Androgen receptor (AR) DTT AR 2.13E-01 -0.07 -0.11
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040072)
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 Phase I clinical trail of PF-06260414 for treating cachexia. Pfizer Inc.